Increase in Fibrinogen and Fibrin-Related Antigen in Human Serum Due to In Vitro Lysis of Fibrin by Thrombin
Open Access
- 1 April 1972
- journal article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 51 (4) , 903-911
- https://doi.org/10.1172/jci106885
Abstract
In vitro lysis of fibrin, as indicated by increased fibrinogen-fibrin-related antigen (FR-antigen) in serum is usually seen when whole blood, or plasma, or highly purified fibrinogen prepared by several different procedures is clotted and kept at temperatures above 0°C. This increase is both time and temperature dependent, occurs despite the addition of various plasmin and cathepsin inhibitors, and is probably caused by thrombin evolved during clotting and/or added in vitro. In these experiments, the FR-antigen was measured by a sensitive, reproducible hemagglutination inhibition immunoassay adapted to the AutoAnalyzer. Serum from whole blood contained more than serum from plasma, and fibrin rather than fibrinogen proved to be essential for the in vitro lysis. The phenomenon was also caused by Arvin or Reptilase, suggesting that splitting of one or more arginine or lysine bonds in fibrin may be at least partially responsible. To obtain minimal levels of FR-antigen (< 0.5 μg/ml), plasma is clotted for 4 hr at 0°C with 1.0-5.0 U/ml thrombin, CaCl2 (0.0125 mole/liter), and epsilon aminocaproic acid (0.05 mole/liter). Slightly higher levels, probably adequate for clinical diagnosis, are obtained by 10-30 min clotting at room temperature. Since endogenous and/or exogenous thrombin is essential for the collection of serum FR-antigen, all the FR-antigen found in normal serum probably results from an irreducible amount of in vitro lysis rather than from continuous intravascular clotting and fibrinolysis.Keywords
This publication has 14 references indexed in Scilit:
- The proteolytic action of the snake venom enzymes arvin and reptilase on N‐terminal chain‐fragments of human fibrinogenFEBS Letters, 1971
- Detection of serum fibrinogen and fibrin degradation products: Comparison of six technics using purified products and application in clinical studiesThe American Journal of Medicine, 1971
- Large-Scale Production of Intermediate-Purity, Soluble Human PlasminogenThrombosis and Haemostasis, 1971
- Partial purification and properties of a plasminogen activator from human erythrocytesJournal of Clinical Investigation, 1969
- Demonstration of Fibrinolytic Split Products in Human Serum by an Immunological Method in Spontaneous and Induced Fibrinolytic StatesScandinavian Journal of Haematology, 1964
- An Immunological Method for Demonstrating Fibrin Degradation Products in Serum and its Use in the Diagnosis of Fibrinolytic StatesBritish Journal of Haematology, 1963
- Fibrinolytic Activity of Human ErythrocytesNature, 1963
- The purification and properties of a proteolytic enzyme, rabbit cathepsin E, and further studies on rabbit cathepsin DBiochemical Journal, 1962
- The Action of Plasmin on Fibrin and Fibrinogen in Blood.1Acta Physiologica Scandinavica, 1953
- Thrombin and Thrombin-ProteaseNature, 1952